phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Oxeia Pioneering First Potential FDA-Approved Concussion Treatment

Oxeia Biopharmaceuticals today launched an equity crowdfunding campaign on StartEngine to advance OXE103, a therapy for persistent concussion symptoms that demonstrated an 85% responder rate in Phase 2a clinical testing.

January 7, 2026


January 15 2026

January 14 2026

January 13 2026

January 12 2026

January 11 2026

January 10 2026

January 9 2026

January 8 2026

January 7 2026

January 6 2026

January 5 2026

January 4 2026

January 3 2026

January 2 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy